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Multiplex strand displacement amplification (mSDA) is capable of amplifying three distinct DNA sequences
simultaneously. These include sequences present in most genera of mycobacteria, a sequence specific for
Mycobacterium tuberculosis, and an internal control. mSDA was used to detect the presence of these target
sequences in 154 (72 positive, 76 negative, and 6 failed) clinical specimens cultured in the mycobacterial growth
indicator tube (MGIT) system. A wide variety of specimen types were processed and cultured. Once these
cultures were deemed positive by MGIT fluorescence or were deemed negative after 8 weeks of incubation,
MGIT culture aliquots were processed for mSDA analyses. A chemiluminescent microwell assay was used to
detect the amplified products. The procedure was relatively simple and took less than 6 h to complete. The
sensitivity of mSDA for detecting acid-fast bacilli was 96.4% compared to that of MGIT culture. Sensitivity and
specificity were 97.2 and 96.1%, respectively, when all clinical criteria were considered. mSDA was shown to be
a rapid and effective method for confirming the presence of M. tuberculosis and other mycobacteria in positive
MGIT cultures.
The rise in the incidence of tuberculosis seen in this country
since 1985 coupled with outbreaks of multidrug-resistant
isolates of Mycobacterium tuberculosis has generated consider-
able interest and research in molecular diagnostic tech-
niques for the mycobacteriology laboratory. Ideally, an am-
plification system should be more sensitive than microscopic
examination, should be at least as sensitive as culture methods,
should accurately confirm the identity of acid-fast bacilli
(AFB) present in positive specimens and cultures, and should
provide the information in a timely manner. Many clinical
laboratories (5, 7, 10, 13, 18) have used in-house assays to
amplify specific nucleotide sequences for the detection of M.
tuberculosis in clinical specimens. Commercially available am-
plification systems (1, 2, 14, 22) are being developed and eval-
uated for the detection and identification of AFB in clinical
specimens and in culture. The application of these assays for
culture identification is gaining popularity because of the ob-
served sensitivity, specificity, and timeliness of testing (9). It
should be possible to design a panel of primers to identify
commonly isolated AFB to the species level, thereby eliminat-
ing time-consuming biochemical identification. Most laborato-
ries will continue to culture AFB regardless of the sensitivity of
the amplification assay in order to determine the drug suscep-
tibility of the causative organism.
Strand displacement amplification (SDA) has been used to
amplify the M. tuberculosis-specific IS6110 element from puri-
fied DNA. Recently (6), SDA was used to detect M. tubercu-
losis in clinical specimens by using this same M. tuberculosis
marker. This study was designed to determine if multiplex
SDA (mSDA) could be used to accurately identify AFB
present in the mycobacterial growth indicator tube (MGIT)
system as soon as the MGIT becomes positive (fluorescent).
mSDA is a DNA amplification technology in which three tar-
get sequences are amplified simultaneously. The three target
gene sequences amplified in this study were 16S ribosomal
DNA (rDNA), IS6110, and an internal control (IC). The 16S
rDNA mycobacterial genus target (MGEN) is present in most
clinically significant mycobacteria, including M. tuberculosis
complex, M. avium, M. intracellulare, M. paratuberculosis, M.
abscessus, M. fortuitum, M. chelonae, M. gordonae, M. kansasii,
M. flavescens, M. gastri, M. scrofulaceum, M. ulcerans, M. ma-
rinum, M. leprae, M. terrae, M. malmoense, M. szulgai, and M.
asiaticum. The MGEN target is not present inM. genevense,M.
celatum, and M. simiae. Amplification of the insertion element
IS6110 indicates the presence of mycobacteria of the M. tu-
berculosis complex (21). The IC is used as an amplification
control to indicate the presence of inhibitors in the prepared
specimen which may yield a false-negative result. The four
possible outcomes obtained from mSDA are (i) the specimen
is negative (MGEN negative, M. tuberculosis negative, and IC
positive); (ii) the specimen contains a mycobacterium species
other than M. tuberculosis (MGEN positive, M. tuberculosis
negative, and IC positive); (iii) the specimen contains M. tu-
berculosis (M. tuberculosis and IC positive); and (iv) the reac-
tion failed (IC negative), indicating that inhibitors are present
and the presence or absence of AFB cannot be determined.
(This study has been previously presented in part [12].)
MATERIALS AND METHODS
Specimens. All clinical specimens, except blood, submitted for AFB culture
were included in this study. Standard N-acetyl-L-cysteine sodium hydroxide di-
gestion, decontamination, and concentration methods (16) were used on non-
sterile specimens. All stool specimens and respiratory specimens from patients
with cystic fibrosis were further decontaminated with oxalic acid (26). MGITs
* Corresponding author. Mailing address: UNC Hospitals, Clinical
Microbiology, CB 7600, Chapel Hill, NC 27514. Phone: (919) 966-
7894. Fax: (919) 966-0486.
† Present address: Ege University, Izmir, Turkey.
‡ Present address: State University of New York, Health Science
Center, Syracuse, N.Y.
1239
and BACTEC 460 bottles (B460) each received 0.5 ml of the specimen, while two
Lowenstein-Jensen (LJ) slants were each inoculated with 0.1 ml of specimen.
The majority of specimens were processed within 24 h, and smears were pre-
pared by fluorochrome staining (16). MGITs were read daily for 8 weeks, B460
readings were performed twice weekly for 2 weeks and once weekly for 2 addi-
tional weeks, and LJ slants were examined weekly for 8 weeks. MGITs and LJ
slants from smear-positive specimens were held for up to 12 weeks. Isolates of
AFB were identified by standard biochemical tests (16) and DNA-RNA hybrid-
ization (Gen-Probe AccuProbe, San Diego, Calif.).
Culture preparation for mSDA. Aliquots were taken for mSDA analysis when
the MGIT culture became fluorescent. In addition, an aliquot was taken from the
MGIT when the B460 culture became positive if this occurred prior to the MGIT
culture becoming positive. Aliquots of negative MGIT cultures were taken at the
end of 8 weeks. At the indicated time, a 1-ml aliquot of the MGIT culture was
processed for mSDA. The aliquot was centrifuged for 1 min at 13,000 3 g. The
supernatant was discarded, and the pellet was resuspended in 1 ml of KPDG
(32.5 mM K2HPO4 [pH 7.6], 7.5% dimethyl sulfoxide, 3% glycerol, 0.01%
NaN3). The sample was centrifuged again at 13,000 3 g for 1 min. The super-
natant was discarded, and the pellet was resuspended in 1 ml of KPDG. A third
centrifugation for 1 min at 13,000 3 g was performed, and the supernatant was
discarded. The pellet was then resuspended in 1 ml of KPDG containing 1 mg of
proteinase K (Sigma Chemical Co.)/ml. The sample was incubated at 558C for 30
min and then incubated at 1008C for 30 min in order to kill any mycobacteria
present in the sample (27) and to release DNA for amplification. The sample was
cooled to room temperature, vortexed, and stored at 2708C until the mSDA
procedure was performed.
SDA. SDA is an isothermal in vitro DNA amplification technique. This am-
plification technique employs a restriction enzyme and a DNA polymerase with
displacement properties to generate multiple copies of a target DNA sequence.
Adapter-mediated mSDA simultaneously amplifies three target sequences, re-
sulting in the detection of the mycobacterium genus (16S rDNA),M. tuberculosis
(IS6110), and an IC while only using two primers. A complete explanation of
SDA and mSDA is offered by Walker et al. (23–25).
mSDA assay. mSDA was performed essentially as described by Walker et al.
(25) except that dUTP was used instead of TTP to allow removal of contami-
nating amplicons. The final concentrations or amounts of components were as
follows: 45 mM K2HPO4 (pH 7.6); 7.5% dimethyl sulfoxide; 3% glycerol; 0.1 mg
of bovine serum albumin/ml; 0.5 mM (each) primer; 0.05 mM (each) adapter;
0.025 mM (each) bumper; 0.5 mM 29-deoxyadenosine 59-O-(1-thiotriphosphate),
0.2 mM (each) dGTP, dCTP, and dUTP; 500 copies of the internal control
sequence; 150 U of HincII; 4 U of exo-Klenow polymerase; 0.5 U of uracil-d-
glycosylase (UDG); 2 U of UDG inhibitor; and 6.5 mM Mg(C2H3O2)2. With
each mSDA batch run, controls containing various copy numbers of Mycobacte-
rium bovis genomic DNA were also tested. This provided a run-to-run calibration
and a within-run control on the efficiency of mSDA. The genomic controls were
diluted in KPDG containing 10 ng of human DNA/ml such that 0, 50, 100, 250,
or 500 copies of M. bovis genomic DNA were contained in 25 ml. M. bovis
controls were tested in triplicate. All components except enzymes, magnesium
acetate, and the UDG inhibitor were combined with 25 ml of the mSDA-
processed MGIT sample or the M. bovis genomic control. This mixture was
vortexed and heated for 2 min at 958C and then incubated at 418C for 5 min.
UDG was added, and the sample was incubated at 418C for 10 min. A mixture
containing the enzymes, UDG inhibitor, and magnesium acetate was then added,
and the resulting mixture was incubated for 2 h at 418C. The final reaction volume
was 50 ml. The reaction was stopped by heating for 2 min at 958C. The sample was
immediately assayed in the microwell assay or was stored at 2208C until tested.
Frozen mSDA samples were heated for 2 min at 958C prior to being assayed.
Chemiluminescent assay. The chemiluminescent microwell assay was per-
formed as described by Spargo et al. (20). The microwell assay is a chemilumi-
nescent enzyme-linked immunosorbent assay utilizing a streptavidin-coated mi-
crowell plate and biotin-labeled DNA probes for capture of the amplified
product. An alkaline phosphatase-labeled DNA probe binds to the mSDA prod-
uct and produces light in the presence of a chemiluminescent substrate. The light
produced is detected with a photomultiplier tube, and the results are given in
relative light units (RLU). For each microwell batch run, synthetic DNA assay
controls were tested along with the mSDA reaction mixtures. The controls were
single-stranded synthetic-target DNA containing dU for dT and were designed to
match the sequence of the mSDA-generated products. The controls were diluted
in a buffer containing all components of the mSDA reaction mixture except the
enzymes and the inhibitor since they do not affect the mSDA result.
The assay was performed as follows. Completed mSDA reaction mixtures and
synthetic target dilutions were heated at 958C for 2 min to denature the DNA.
The solutions were cooled for 5 min at room temperature, and 10 ml of the
denatured sample was added to each well. Assay synthetic target controls were
tested in duplicate; mSDA reactions were tested as single points. Immediately
thereafter, 90 ml of hybridization buffer (0.05 M Trizma base [Sigma], 0.9 M
NaCl, 0.05 mM ZnCl2 [Sigma], 0.1% bovine serum albumin [Sigma], 0.2% NaN3,
10.2 mg of salmon sperm DNA [Sigma]/ml, 2% trehalose [Quadrant; pH 7.0],
capture and detector probes [concentrations optimized for high signal and low
backgrounds]) was added. The microwell plate was covered and incubated for 45
min at 378C. Three stringency washes (10 mM Trizma base, 0.1% bovine serum
albumin, 0.01% Nonidet P-40 (Sigma), 250 mM NaCl, 0.1% NaN3 [pH 7.5]) of
300 ml each were performed at room temperature. One hundred microliters of
the chemiluminescent substrate Lumiphos 530 (Lumigen Inc.) was added to each
well. The plates were covered and incubated at 378C for 30 min. Luminescence
(RLU) was read on a microwell plate luminometer (Labproducts TM, Research
Triangle Park, N.C.) at 378C, with a 2 s/well integration time.
Statistical analysis. The mSDA, MGIT, and B460 results for the 154 speci-
mens were compiled and stored along with sample type (sputum, urine, etc.) and
additional therapy data as available. The mSDA assay produces a quantitative
luminescence result (RLU) which does not immediately fall into defined cate-
gories of positive and negative. In fact, there are an infinite number of possible
cutoff values above which one could declare a positive result. Also, the mSDA
assay procedure was done in seven batches of about 20 samples per batch plus
controls. Thus, the RLU response for the clinical samples may be calibrated via
the controls included with each batch. This provides a way of removing day-to-
day variability in the mSDA assay, as captured by the controls, to assist in
deciding whether a clinical sample is positive or negative by mSDA. A plot of
RLU values obtained for several levels of mSDA controls is given in Fig. 1. This
also shows reproducibility and minimum detectable concentration (MDC) of the
mSDA assay detection system. The MDC is the minimum number of M. bovis
genomes that can be significantly (P , 0.05) distinguished from zero genomes
based on the variability in replicate assays done for each of the positive controls
(17). The MDC is labeled in Fig. 1.
The RLU data were evaluated on several scales, including raw RLU and RLU
normalized by various combinations of the negative, 50-genome and 100-genome
controls. For example, normalizing to the 50-genome positive control was
achieved by dividing RLU values obtained for a particular batch of clinical
samples by the mean RLU of the 50-genome positive control run with that batch
of clinical samples and multiplying the result by 50. Fluctuations in RLU values
for different batches are accounted for by this process. Actual cutoff values for
each method were chosen from a cutoff plot as described below. Receiver
operator characteristic (ROC) curves were used to compare the accuracies and
discrimination abilities of the methods. An ROC curve is a plot of true-positive
rate versus false-positive rate. The true-positive rate is equivalent to sensitivity
(expressed as a proportion) and is the probability of a positive (mSDA) test for
individuals in whom the presence of mycobacteria has been shown by one of the
culture systems: MGIT, B460, or LJ slants. The false-positive rate is equivalent
to one minus the specificity and is the probability of a positive (mSDA) test for
individuals in whom the absence of mycobacteria has been shown by MGIT,
B460, and LJ slants. The ROC curve captures the trade-off between sensitivity
and specificity and quantifies the accuracy of diagnostic test methods (6, 11).
The area under the ROC curve may be used to quantify and compare ROC
curves. Often, smooth curves are fit to ROC curves when comparing diagnostic
tests (11). In our application we compared ROC curves to assess different cutoff
strategies for the same set of data. The area under the empirical ROC curve thus
provided a more accurate comparison and was used to identify a satisfactory
scale for summarizing the RLU data.
A cutoff plot for the mSDA results, normalized to the 50-genome control and
with the culture result as the reference, is given in Fig. 2. This is a plot of
sensitivity and specificity versus cutoff values scaled to the 50-genome M. bovis
FIG. 1. SDA positive-control response curve. Shown is a plot of RLU for
samples spiked with fixed quantities of M. bovis genomes. Samples were treated
identically to clinical specimens with regard to both amplification and detection.
The solid line indicates a least-squares linear regression fit. The dotted lines
indicate 95% confidence limits for fit. The MDC of 50 M. bovis genomes is
marked on the plot. The MDC is the lowest concentration of M. bovis genomes
which results in an expected response (RLU value) that is significantly greater
than the response for zero M. bovis genomes.
1240 BADAK ET AL. J. CLIN. MICROBIOL.
standard. The cutoff plot allows visual selection of a cutoff value for a desired
value of either sensitivity or specificity.
RESULTS
Culture and mSDA findings. During this study we per-
formed mSDA analysis on 154 samples (Table 1) selected from
800 MGIT cultures that had been inoculated with a variety of
clinical specimens. As shown, the majority of specimens were
from respiratory sources (133 of 154, 86%). MGIT cultures
were selected for mSDA analysis based on one of the five
categories shown in Table 2. As shown, 55 of the 154 MGIT
samples tested (category 1) were from MGIT cultures which
grew M. tuberculosis (11 isolates) or other AFB (MOTT; 44
isolates). Of the 55 culture-positive MGIT specimens tested,
53 were mSDA positive for the appropriate organism, resulting
in a sensitivity of 96.4%. There were 19 additional mSDA-
positive findings. Seventeen (category 2) of these were from
MGIT cultures which became fluorescent but did not grow
AFB. A chart review indicated that only 2 (category 2.4) of
these 17 were likely mSDA false-positive results. The other 15
mSDA positives were from patients who had had other cul-
tures positive for AFB or who were receiving antimycobacte-
rial therapy. The majority of the 37 specimens from category
2.4 which fluoresced but did not grow AFB were from MGIT
cultures that had been incubated #3 days. Most were fluores-
cence negative by day 5 of incubation. The 33 specimens from
category 3 which fluoresced but grew bacteria or fungi are also
relevant to the testing of MGIT fluorescent cultures since AFB
may or may not be present in cultures contaminated with
bacteria or fungi. All but 1 of the 33 specimens in category 3
were mSDA negative and were from patients with no cultural
or clinical evidence of mycobacterial infection. The 13 speci-
mens in category 4 could be considered negative controls;
however, these specimens would not be tested if one were to
use mSDA on positive MGIT cultures only. Considering all
clinical and cultural findings, the overall sensitivity and speci-
ficity were 97.2 and 96.1%, respectively, when mSDA was used
to test MGIT fluorescent cultures. The positive predictive
value was 95.8%, and the negative predictive value was 97.4%.
The sensitivity of mSDA was calculated as tp/(tp 1 fn), where
tp is the number of true positives and fn is the number of false
negatives. From Table 2, the number of true positives is 53 1
51 71 31 15 69 and the number of false negatives is 2; thus,
the sensitivity of mSDA compared to culture is 69/71, or
97.2%. The specificity of mSDA was calculated as tn/(tn 1 fp),
where tn is the number of true negatives and fp is the number
of false positives. From Table 2, the number of true negatives
is 30 1 32 1 12 5 74 and the number of false positives in 2 1
1 5 3; thus, the specificity of mSDA is 74/77, or 96.1%. The
positive predictive value of mSDA was calculated as tp/(tp 1
FIG. 2. ROC cutoff plot of mSDA test for the Mycobacterium genus, with
positive culture from either MGIT, B460, or LJ slants as the reference method.
The intersection of the horizontal dotted line with the sensitivity and specificity
curves indicates 95% cutoffs for sensitivity and specificity. The vertical dotted line
represents the chosen cutoff at 4 normalized RLU. These normalized units are
proportional to the number ofM. bovis genome equivalents per mSDA reaction.
TABLE 1. Sources of 154 specimens used to inoculate MGIT
Specimen source No. tested(failed)
Respiratory..................................................................................... 133
Sputum........................................................................................ 94 (1)
Bronchoalveolar lavage ............................................................ 16 (1)





Bone marrow ............................................................................. 4 (4)
Urine........................................................................................... 3
Gastric aspirate.......................................................................... 2
Peritoneal aspirate .................................................................... 1
Pericardial aspirate ................................................................... 1
Abscess (wound)........................................................................ 1
TABLE 2. MGIT versus SDA results
MGIT categorya No. ofsamplesb
No. of samples
SDA positive
1. F1 C1 (total true positives) 55 53
1.1. MGIT culture grew MOTT 44 43
1.2. MGIT culture grew M. tuberculosis 11 10
2. F1 C2 52 (5) 17
2.1. Subsequent MGIT culture positive 5 5
2.2. Positive B460 or LJ culture 7 7
2.3. Patient on TB medication 3 3
2.4. MGIT false-positive fluorescencec 37 (5) 2
3. F1 C1 (culture grew bacteria or fungi) 33 1
4. F2 C2 (control true negative) 13 (1) 0
5. F2 C2 (AFB cultured in B460 or LJ slants) 1 1
Total specimens tested 154 (6) 72
a F1, fluorescence positive; F2, fluorescence negative; C1, culture positive;
C2, no organisms cultured; TB, tuberculosis.
b Numbers in parentheses indicate numbers of failed SDA reactions; these
were not included in the statistical analysis.
cMajority of MGITs became fluorescent in #3 days.
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fp) 5 69/72, or 95.8%. The negative predictive value of mSDA
was calculated as tn/(tn 1 fn) 5 74/76, or 97.4%.
There were six specimens (Table 1) that contained inhibi-
tor(s) to the mSDA reaction. No AFB were isolated from the
six MGIT cultures with a failed mSDA result. All four bone
marrow specimens selected for mSDA testing failed to amplify
the internal signal (control sequence).
The RLU results for a typical mSDA batch run are shown in
Table 3. All possible results are shown, i.e., when M. tubercu-
losis is present, when MOTT are present, when the specimen is
negative for AFB, and when the reaction fails due to internal
inhibitors present within the test specimen.
Statistical analysis.Normalizing the RLU values of the clinical
specimens to the 50-genome positive control gave a slightly more
discriminating decision procedure than choosing a single fixed
cutoff value as measured by the area under the ROC curve. Note
that with just seven batches of mSDA data one would not expect
much difference. This may, however, be more relevant in a re-
peat-use clinical setting with multiple locations and batches, pro-
vided the controls track variability over such locations and
batches. The cutoff plot for data normalized to the 50-genome
positive control is given in Fig. 2. Subsequent summaries and
analyses are based on data normalized to the 50-genome control.
The cutoff value that allows detection of 95% of culture-
positive specimens is given by the intersection of the sensitivity
curve with the dotted line in Fig. 2 and corresponds to about 4
U on the normalized RLU scale. This scale is proportional to
the number of genome equivalents in the clinical samples. In
general, cutoff selection for the mSDA procedure requires
assessment of the relative importance of sensitivity and speci-
ficity. For example, one may choose to minimize the risk func-
tion Rc 5 L1(12sensc)p 1 L2(12specc)(12p), where Rc is the
overall risk; sensc is the sensitivity and specc is the specificity as
a function of the cutoff, c; L1 is the loss associated with a
false-negative result; L2 is the loss associated with a false-
positive result; and p is an estimate of the probability, in the
laboratory population, that a sample will contain an AFB.
DISCUSSION
The use of metabolic indicators of growth such as CO2
production, change in atmospheric pressure, or utilization of
O2 has reduced the incubation time needed to detect the pres-
ence of microorganisms in clinical specimens. This is especially
true for slowly growing organisms such as mycobacteria. Mo-
lecular techniques such as PCR and other nucleic acid ampli-
fication techniques (NAAT) are capable of detecting and iden-
tifying mycobacteria in a few hours. The sensitivities of these
NAAT when applied to direct clinical specimen testing have been
found to be higher than that of microscopic examination but
somewhat lower than that of conventional culture methodology
(3, 8, 19). The cost-effectiveness of performing NAAT on smear-
positive specimens seems justifiable since therapeutic and isola-
tion issues can be resolved in a timely manner. The cost-effec-
tiveness of performing NAAT on all incoming specimens has yet
to be established. Besides cost-per-test issues, the major factors
related to this uncertainty include (i) the lack of sensitivity of
NAAT due to inhibitors in the clinical specimen or due to inef-
ficient cell breakage and release of target DNA, (ii) the rare
incidence of tuberculosis and other mycobacterial diseases in
many patient populations, and (iii) the lack of specificity of
NAAT due to the presence of environmental contaminants or
due to the presence of dead mycobacteria following antimycobac-
terial therapy. These concerns, coupled with antimycobacterial
susceptibility testing requirements, allow NAAT to supplement
rather than replace routine culture for AFB.
In addition, NAAT should be useful for testing cultured
specimens of AFB that have become positive. We applied one
such NAAT (mSDA) for rapid evaluation of a particular my-
cobacterial growth detection system (MGIT). The time to de-
tection for the MGIT system is comparable to that of the B460
system (4, 15). We used MGIT fluorescence as a selective
criterion for inclusion in the mSDA analysis. Historically, spec-
imens submitted for AFB cultures have a positivity rate near
7% at our institution. M. tuberculosis accounts for less than
15% of those positive cultures (,30 patients/year). During this
study 11 of the 55 positive cultures were positive for M. tuber-
culosis (20%). The 55 positives were selected from 800 MGIT
cultures during this study period. We chose to test MGIT
positives as well as a few negatives rather than test all 800
MGIT cultures. The sensitivity of mSDA for testing fluorescence-
positive MGIT specimens obtained in this study is probably ac-
curate; however, the specificity might have been different had all
800 specimens been tested. The specificity might have improved
since no false positives were detected in categories 4 and 5. The
three false positives occurred in categories 2.4 and 3 in which
MGIT specimens did become fluorescence positive.
Although these three results were presumed to be false-
positive mSDA reactions, one cannot rule out the presence of
low numbers (negative smears) of dead mycobacteria derived
from environmental sources (food or water). Concentrated
preparations from these three MGIT specimens were AFB
negative by microscopic examination. Regardless of the three
false-positive mSDA results, which lower the specificity, there
were no false reactions between the M. tuberculosis and
TABLE 3. RLU readings obtained by mSDA
Culture
no.
mSDA signal (RLU)a for: Result
M. tuberculosis MGEN IC SDA Culture MGITcategoryb
345 25 36 14,273 —c — 3
382 23 19 1,646 — — 3
354 24 73,771 13,573 MOTT MACd 1.1
111 43,792 66,800 33,372 MTBe MTB 2.2
150 29 32 12,632 — — 2.4
305 25 6,908 11,273 MOTT MAC 1.1
343 27 25 13,559 — — 2.4
160 28 21 10,802 — — 2.4
171 25 21 11,587 — — 4
364 26 47 10,127 — — 4
357 21 117 13,992 — — 3
29 26 57,189 12,323 MOTT MAB f 1.1
12 44,362 83,302 28,646 MTB MTB 1.2
180 26 29 8,591 — — 2.4
40 36 30 10,432 — — 2.4
50 29 23 2,042 — Bacteria 3
282 25 1,796 11,462 MOTT MAC 2.2
65 28 23 8,945 — — 4
229 29 55,197 10,839 MOTT MAB 1.1
22 27 48 10,593 — — 4
66 37 45 12,865 — — 4
424 26 28 11,460 — — 3
9 50,057 84,846 35,726 MTB MTB 1.2
186 39 49 15.4 Failed — 2.4
476 48 24 10,302 — — 4
a Cutoffs for this batch are as follows:M. tuberculosis, 2,000 RLU; MGEN, 320
RLU; IC, 100 RLU.
bMGIT categories are as defined in Table 2.
c—, negative result.
dMAC, M. avium complex.
eMTB, M. tuberculosis.
fMAB, M. abscessus.
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MGEN mSDA results. For all specimens positive for AFB by
culture, whether grown in MGIT, B460, or LJ slants, when the
mSDA result was positive, it was correct (M. tuberculosis versus
MOTT). Thus, the mSDA system does have a major advantage
over other NAAT that are designed to detect only M. tubercu-
losis and an IC. Detection of MGEN and the IC with a negative
M. tuberculosis result by mSDA gives a high degree of confi-
dence that the patient does not have tuberculosis and can be
removed from isolation. Although one can argue that the pa-
tient may have both MOTT and a small amount of M. tuber-
culosis, a condition resulting in a negative M. tuberculosis
mSDA signal, this is true for any NAAT or culture method
used in the mycobacteriology laboratory. The six mSDA fail-
ures represented a 4% failure rate, which leads to increased
laboratory expenses in terms of labor and materials. It may be
possible to reduce the failure rate by additional processing
steps prior to mSDA analysis of bone marrow specimens.
Another area of concern for our laboratory was how adapt-
able the mSDA assay might be for a clinical mycobacteriology
laboratory. In this study, five different individuals performed
the mSDA assay. After being processed, the MGIT culture
aliquots were stored and batch processed at Becton Dickinson
Research Center (BDRC). Each technologist performed the
mSDA and the chemiluminescence assays on a minimum of 40
MGIT samples plus controls. All stock reagents were available
at BDRC; therefore, there was a minimum of pipetting, prep-
aration of buffers, etc. In addition, the microwell chemilumines-
cence trays were already prepared. Thismanual hands-onmeth-
od provided results in approximately 4 h. Routine testing of 1
to 30 specimens each day would prove cumbersome given the
manual nature of the current assay methods. This technology
can presumably be automated, thus making it more attractive
to most clinical laboratories. With a cost-effective automated
system one could also argue that AFB culture incubation times
might be greatly reduced by using NAAT technology. For in-
stance, mSDA or other NAAT might allow incubation of AFB
cultures to end after 7 to 14 days if the sensitivity is sufficiently
high and the cost per test is sufficiently low. Compared to the
alternative of 8 weeks of incubation, NAAT would represent
significant improvement in labor, work flow, and instrumenta-
tion issues in the AFB laboratory. Considerable research re-
mains to be done before the value of mSDA or other NAAT be-
comes clearly established in the mycobacteriology laboratory.
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